Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Sarah Cannon Research Institute, Nashville, TN, United States



Survival: 8.6 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
   
Drugs:
Country: United States
   
City/State/Province: Nashville, TN
   
Hospital: Sarah Cannon Research Institute
   
Journal: Link
   
Date: 9/2010

Description:
Patients:
This phase II study involved 57 patients with metastatic melanoma. The median age was 70 years and 68% of patients were male.

Treatment:
Patients were administered a combination of two biologic therapies bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) protein, and everolimus, an mTOR inhibitor. Both agents inhibit cancer cell division and stop blood vessel growth in tumors.

Toxicities:
One death due to heart attack was reported for this study. Other toxicities reported were of grade 3 or less, the most common grade 3 toxicities being fatigue, stomatitis, and hypertension.

Results:
Median overall survival for this study was 8.6 months and median progression-free survival was 4 months.

Support:
This study was partially supported by Genentech and Novartis, makers of bevacizumab (brand name Avastin) and everolimus (brand name Afinitor), respectively.

Correspondence: Dr. John D. Hainsworth; email: jhainsworth@tnonc.com

E-mail to a Friend Email Physician More Information